| 01.08 12:59 | dpa-AFX: ROUNDUP: Regeneron Pharma Q2 Results Top Estimates |
| 01.08 12:50 | dpa-AFX: *REGENERON PHARMA Q2 GAAP NET INCOME $1.432 BLN; NON-GAAP NET INCOME $1.351 BLN |
| 01.08 12:49 | dpa-AFX: *REGENERON PHARMA Q2 REVENUES UP 12% TO $3.55 BLN |
| 01.08 12:33 | dpa-AFX: *REGENERON PHARMA Q2 GAAP EPS $12.41; NON-GAAP EPS $11.56 |
| 30.07 10:19 | dpa-AFX: Biotech Stocks Facing FDA Decision In August 2024 |
| 29.07 10:15 | dpa-AFX: Biotech Stocks Facing FDA Decision In August 2024 |
| 10.07 09:53 | dpa-AFX: *BARCLAYS HEBT ZIEL FÜR REGENERON PHARMA AUF 1200 (1050) USD - 'OVERWEIGHT' |
| 10.07 09:53 | dpa-AFX: *BARCLAYS RAISES REGENERON PHARMA PRICE TARGET TO 1200 (1050) USD - 'OVERWEIGHT' |
| 08.07 14:05 | dpa-AFX: Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge |
| 08.07 13:58 | dpa-AFX: *REGENERON ANTICIPATES $24 MLN R&D CHARGE IN Q2 RESULTS |
| 03.07 08:15 | dpa-AFX: Sanofi-Blockbuster Dupixent: Zulassung in Europa für spezielle Lungenkrankheit |
| 03.07 08:15 | Sanofi-Blockbuster Dupixent: Zulassung in Europa für spezielle Lungenkrankheit |
| 03.07 08:10 | dpa-AFX: Sanofi-Blockbuster Dupixent: Zulassung in Europa für spezielle Lungenkrankheit |
| 03.07 07:39 | Sanofi erhält EU-Zulassung für Dupixent als COPD-Therapie |
| 03.07 07:31 | dpa-AFX: Regeneron, Sanofi: EU Approves Dupixent As First-ever Targeted Therapy For COPD Patients |
| 03.07 07:11 | dpa-AFX: *REGENERON: EC APPROVES DUPIXENT AS ADD-ON MAINTENANCE TREATMENT FOR ADULTS WITH COPD |
| 28.06 13:20 | dpa-AFX: Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU |
| 28.06 13:11 | dpa-AFX: *REGENERON: ODRONEXTAMAB RECOMMENDED FOR EU APPROVAL BY CHMP TO TREAT R/R FOLLICULAR LYMPHOMA AND DLBCL |
| 11.06 13:51 | dpa-AFX: Regeneron, Sanofi Report FDA Approval Of Kevzara To Treat Active PJIA |
| 11.06 13:04 | dpa-AFX: *REGENERON AND SANOFI: FDA APPROVES KEVZARA FOR TREATMENT OF ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS |
|
|
